Cationic lipid–protamine–DNA (LPD) complexes for delivery of antisense c-myc oligonucleotides
In the present study, cationic lipid–peptide–DNA-complexes (LPDs) consisting of AH-Chol-liposomes and protamine–phosphodiester–oligonucleotide-particles (proticles) were introduced as carriers for antisense therapy. The LPDs were physically characterized, and a possible mechanism for adsorption of o...
Gespeichert in:
Veröffentlicht in: | European journal of pharmaceutics and biopharmaceutics 2005-07, Vol.60 (2), p.287-294 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | In the present study, cationic lipid–peptide–DNA-complexes (LPDs) consisting of AH-Chol-liposomes and protamine–phosphodiester–oligonucleotide-particles (proticles) were introduced as carriers for antisense therapy. The LPDs were physically characterized, and a possible mechanism for adsorption of oligonucleotides (ODNs) was suggested. An increase in stability of ODNs against DNase I and serum nuclease digestion by these carriers was demonstrated. The hydrodynamic diameter increased after incubation with FCS which could be attributed to a protein coating of the particle surface. However, in cell culture medium lower particle sizes of the complexes occurred. In an antisense
c-myc in vitro model, the effect of LPDs was tested using U937 cells. The C-MYC level was reduced after treatment of these antisense ODN carrier complexes. Furthermore, no changes in target mRNA concentration of the treated cells was found by reverse transcription and competitive multiplex-PCR. |
---|---|
ISSN: | 0939-6411 1873-3441 |
DOI: | 10.1016/j.ejpb.2005.01.006 |